Arcturus Therapeutics (ARCT) Misses Q2 EPS by $3.55
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Join SI Premium – FREE
Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.34), $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $0 versus the consensus estimate of $191.77 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
- Jefferies sees metals breakout on currency concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
